A monthly recap of the latest news about Alzheimer’s and dementia


Scientists look to people with Down syndrome to test Alzheimer’s drugs

The condition of brain inflammation, commonly observed in those with down syndrome, plays an important role in Alzheimer’s. Read more here.


New Dementia Prevention Method May Be Behavioral, Not Prescribed

As experimental drugs prove ineffective against increasing dementia cases in the U.S., researchers argue that improving eyesight can have an effect. Read more here.


Research Spots Gene That Raises Alzheimer’s Risk for Women

Researchers studying genes involved in Alzheimer’s disease have identified a new gene, called MGMT, that increases risk for this common dementia in women. Read more here.


Lab-Grown Mini-Brains Could Help Find Treatments for Alzheimer’s and Other Diseases

Better Alzheimer’s treatments are going to require better models of Alzheimer’s brains in the lab, researchers say. Read more here.

FDA Fast-Tracks Alzheimer’s Drug Lecanemab; Decision Expected By Early 2023

Biogen and Eisai’s next disease-modifying Alzheimer’s drug candidate, lecanemab, has been granted FDA priority review, signaling that a decision could be made by early next year. Read more here.


Two FDA-Approved Drugs May Help Treat Alzheimer’s Symptoms

Dozens of drugs designed to target and clear beta-amyloid plaques in the brain have failed to prevent or halt the progression of Alzheimer’s disease. Despite the shortcomings, several anti-amyloid drug candidates — gantenerumab, lecanemab, donanemab — are in the final stages of clinical trials. Read more here.